Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels

We evaluated responses to the treatment and long-term outcomes of chronic myeloid leukemia patients treated with imatinib as first-line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors (TKIs) treatment. We assessed prognostic significance of Europe...

Descripción completa

Detalles Bibliográficos
Autores principales: Klamová, Hana, Poláková, Kateřina Machová, Mužík, Jan, Ráčil, Zdeněk, Žáčková, Daniela, Steinerová, Kateřina, Karas, Michal, Faber, Edgar, Demečková, Eva, Michalovičová-Sninská, Zuzana, Voglová, Jaroslava, Demitrovičová, Ľudmila, Mikušková, Eva, Tóthová, Elena, Chudej, Juraj, Markuljak, Imrich, Cmunt, Eduard, Moravcová, Jana, Dvořáková, Dana, Michalová, Kyra, Jarošová, Marie, Šťastná, Markéta Marková, Cetkovský, Petr, DuŠek, Ladislav, Koza, Vladimír, Trněný, Marek, Indrák, Karel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639660/
https://www.ncbi.nlm.nih.gov/pubmed/23634289
http://dx.doi.org/10.1002/cam4.59

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639660/
https://www.ncbi.nlm.nih.gov/pubmed/23634289
http://dx.doi.org/10.1002/cam4.59

Ejemplares similares